N/A N=13 Treatment of Egg Allergy in Children Through Oral Desensitization (EGG OIT)
Food Hypersensitivity
Primary: Double-blind, Placebo-controlled Food Challenge (DBPCFC) to Egg — 9 subjects with no symptoms on DBPCFC
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=23 The Effect of Per Oral Immunotherapy in Severe IgE Mediated Egg, Milk, and Nut Allergy in Adults
Food Allergy
Primary: Number of the Patients That Achieve Higher Tolerance of Allergen With Immunotherapy — 6; 4; 3 participants
Phase 2 N=55 Oral Immunotherapy for Childhood Egg Allergy
Hypersensitivity · Immediate Hypersensitivity · Food Hypersensitivity
Primary: Percent of Participants Who Successfully Consumed 10,000 mg of Egg White Solid Followed by Open Feeding of Egg — 27.5; 0 percentage of participants — p=0.025
Phase 2 N=92 Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy
Food Allergy
Primary: Sustained Unresponsiveness to Egg Consumption at 2 Years. — 3; 10; 7 Participants — p=0.009
Phase 2 N=20 Time-limited Specific Oral Tolerance Induction in Children With Severe Egg Allergy
- Egg Hypersensitivity
Primary: Number of Children That Achieved Total (40 ml) or Partial (Less Than 40 ml But at Least 10 ml) Tolerance to Raw Egg — 9; 0 participants
N/A N=30 The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults
Food Allergy
Primary: Desensitisation — 7; 5; 2 Participants
N/A N=31 Safe Administration of Flu Vaccine to Egg Allergic Children
Egg Allergy
Primary: Categorical Reactivity to Vaccine as it Was Administered — 17; 14; 3; 4 Participants
Phase 2 N=75 Peanut Epicutaneous Phase II Immunotherapy Clinical Trial
Peanut Hypersensitivity · Food Hypersensitivity · Hypersensitivity
Primary: Percentage of Subjects With a Successful Treatment Response — 12.0; 45.8; 48.0 percentage of participants — p=0.005
Phase 2 N=640 Promoting Tolerance to Peanut in High-Risk Children
Eczema · Egg Allergy · Food Allergy
Primary: Number of Participants With Peanut Allergy at 60 Months of Age - by Skin Prick Test Stratum — 36; 5; 18; 5 Participants — p=<0.0001
Phase 2 N=36 Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
Peanut Allergy · Food Allergy
Primary: Tolerance of 2000 mg 6 Weeks After Last Dose of Omalizumab/Placebo — 23; 1 Participants
N/A N=20 Immunological Response After Shrimp Oral Immunotherapy Treatment
Allergy to Shrimp · Immunotherapy
Primary: Change in Eliciting Dose of Shrimp During Oral Food Challenge — 3233; 25 mg
Phase 3 N=180 Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants
Peanut Allergy · Multi-food Allergy
Primary: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without…
Phase 1 N=10 Oral AGY for Celiac Disease
Celiac Disease
Primary: Number of Participants for Which Treatment Was Concluded to be Safe — 6; 18; 4; 5 participants
Phase 2 N=13 Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy
Peanut Hypersensitivity
Primary: The Percentage of Subjects Who Pass the 20gm Peanut Flour (~50% Peanut Protein) Oral Food Challenge 2-4 Weeks After Discontinuing Peanut OIT Therapy — 3; 1 Participants
Early Phase 1 N=25 Milk Oral Immunotherapy in Children to Treat Food Allergy
Milk Hypersensitivity
Primary: Number of Subjects Who Completed Desensitization Protocol — 6; 12 participants
N/A N=24 Oral Immunotherapy for Peanut and Mammalian Meat Allergies
Food Hypersensitivity
Primary: The Level of Allergen Consumed Post-oral Immunotherapy — 6; 300 milligrams
Phase 2 N=77 OIT and Xolair® (Omalizumab) in Cow's Milk Allergy
Milk Allergy
Primary: Percentage of Subjects in the Xolair® (Omalizumab) Group vs. Placebo Group Developing Clinical Tolerance to Milk — 46.4; 34.5 Percent of participants — p=0.42
Phase 2 N=14 Omalizumab in the Treatment of Peanut Allergy
Food Allergy · Peanut Allergy
Primary: Number of Participants Who Experienced a Decrease in Pn-BHR Area Under the Curve (AUC) of > 80% Compared With Baseline Values Before Week 8 — 5; 9 Participants
Phase 2 N=60 Multi Immunotherapy to Test Tolerance and Xolair
Food Allergy
Primary: The Number of Participants Able to Tolerate an Oral Food Challenge to 2,000 mg at Least of 2 Allergens at Week 36 (i.e. the End of the Randomized Withdrawal/Tolerance…
N/A N=84 Effect of Chicken Egg Antibody (IgY) on Patients With Chronic Gastritis
Chronic Gastritis Caused by Helicobacter Pylori
Primary: UBT Values at Baseline and 8 Weeks — 161.64; 158.54; 49.42; 73.37 UBT value
N/A N=18 Immune Dysfunction in Allergic Asthma
Asthma
Primary: Anti-KLH Antibody. This is Measured by ELISA and Expressed as ELISA Units Which Are Derived by Dilution of Serum Samples Until the Result Falls on a Linear Portion of…
Phase 2 N=73 ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
Food Allergy
Primary: 600mg Desensitization in at Least One Qualifying Food — 8; 11; 4 Participants
Phase 2 N=10 Preventing Anaphylaxis With Acalabrutinib
Food Allergy · Food Allergy Peanut
Primary: Highest Dose of Peanut That is Tolerated During Oral Food Challenge — 29; 4,044 mg — p=0.002
Phase 2 N=198 Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy
Food Allergy
Primary: Percentage (%) of Subjects Who Are Treatment Responders After 12 Months of EPIT Treatment. — 36.7; 49.0; 36.2; 30.2 percent of participants
Phase 2 N=686 COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
SARS-CoV Infection · COVID-19 · Allergic Reaction
Primary: Proportion of Participants Who Experienced a Systemic Allergic Reaction (CoFAR Grade 2+ Regardless of Tryptase or CoFAR Grade 1 With Elevated Tryptase) Within 90 Minutes…
Phase 2 N=120 The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery
Peanut Allergy
Primary: Passing the Week 117 DBPCFC to Peanut — 21; 19; 1 participants
Phase 4 N=119 TBE (Tick-borne Encephalitis) Vaccination in Allergic Patients
Vaccine Responsiveness in Allergy · Vaccine Responsiveness During Allergy De-sensitization Treatment
Primary: Humoral TBE Immunity — 317.90; 250.10; 282.20 titer
N/A N=46 Predicting Peanut Anaphylaxis and Reducing Epinephrine
Anaphylaxis Food
Primary: Anaphylaxis Occurrence Rates in Each Group — 9; 10 Participants — p=0.77
N/A N=20 Cardioprotective Activities Of Whole Eggs On Vascular Endothelial Function In Prediabetic Adults
Prediabetes · Cardiovascular Disease
Primary: Vascular Endothelial Function — -294.4; -152.9; -102.9; -361.6 %FMD*min
Phase 2 N=253 Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP)
Allergic Skin Reaction
Primary: Positive Allergic Reaction to Amphadase® in the Per-Protocol Population (PPP) — 0 participants